Cost-effectiveness analyses for mirtazapine and sertraline in dementia: Randomised controlled trial

British Journal of Psychiatry

Volumn 202, Issue 2, 2013, Pages 121-128

  Romeo, Renee ^a   Knapp, Martin ^a,b   Hellier, Jennifer ^a   Dewey, Michael ^a   Ballard, Clive ^a   Baldwin, Robert ^c   Bentham, Peter ^d   Burns, Alistair ^c   Fox, Chris ^e   Holmes, Clive ^f   Katona, Cornelius ^g   Lawton, Claire ^h   Lindesay, James ⁱ   Livingston, Gill ^h   Mccrae, Niall ^a   Moniz Cook, Esme ^j   Murray, Joanna ^a   Nurock, Shirley ^k   John O'Brien, ^l   Poppe, Michaela ^a   Thomas, Alan ^l   Walwyn, Rebecca ^a   Wilson, Kenneth ^m   Banerjee, Sube ^n,o   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j UNIVERSITY OF HULL   (United Kingdom)

^k ALZHEIMER'S SOCIETY   (United Kingdom)

^l NEWCASTLE UNIVERSITY   (United Kingdom)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁿ BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^o UNIVERSITY OF SUSSEX   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE; PLACEBO; SERTRALINE;

ARTICLE; CONTROLLED STUDY; CORNELL SCALE FOR DEPRESSION IN DEMENTIA SCORE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEMENTIA; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 84873475592     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.112.115212     Document Type: Article

References (26)

1. Wimo A, Prince M. World Alzheimer's Report 2010 the Global Economic Impact of Dementia. Alzheimer's Disease International, 2010.
2. Comas-Herrera A, Wittenberg R, Pickard L, Knapp M. Cognitive impairment in older people: future demand for long-term care services and the associated costs. Int J Geriatr Psychiatr 2007;22: 1037-45.
3. Devanand DP, Jacobs DM, Tang MX, Del Castillo-Castaneda C, Sano M, Marder K, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54: 257-63.
4. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, De Kosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study. JAMA 2002;288: 1475-83.
5. Steffens DC, Fisher GG, Langa KM, Potter GG, Plassman BL. Prevalence of depression among older Americans: the Aging, Demographics and Memory Study. Int Psychogeriatr 2009;21: 879-88.
6. Kales HC, Blow FC, Copeland LA, Bingham RC, Kammerer EE, Mellow AM. Health care utilization by older patients with coexisting dementia and depression. Am J Psychiatry 1999;156: 550-6.
7. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002;4: CD003944.
8. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005;84: 1-13.
9. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378: 403-11.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA work group. Neurology 1984;34: 939-44.
11. Alexopoulos GA, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatr 1988;23: 271-84.
12. The EuroQoL Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 1990;16: 199-208.
13. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK Population Survey. Discussion Paper 138. University of York, 1995.
14. Beecham J, Knapp M. Costing psychiatric interventions. In Measuring Health Needs (2nd edn) (ed. G Thornicroft): 200-24. Gaskell, 2001.
15. Curtis L. Unit Costs of Health and Social Care. PSSRU, 2010.
16. Department of Health. National Health Service Schedule of Reference Costs 2010. Department of Health, 2011 (http://www.doh.gov.uk/nhsexec/refcosts.htm).
17. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 59. BMA, RPS 2010.
18. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, 2008 (http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf).
19. Knapp M, Thorgrimsen L, Patel A, Spector A, Hallam A, Woods B, et al. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis. Br J Psychiatry 2006;188: 574-80.
20. Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. Randomised controlled trial to determine the clinical effectiveness and costeffectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 2009;13: 1-159.
21. Appleby J, Devlin N, Parkin D. NICE's cost-effectiveness threshold: how high should it be? BMJ 2007;335: 358-9.
22. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002;46: 197-201.
23. Muhlbacher M, Konstantinidis A, Kasper S, Eichberger G, Hinterhuber H, Hofmann P, et al. Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. Neuropsychobiology 2006;53: 83-87.
24. Naglie G, Tomlinson G, Tansey C, Irvine J, Ritvo P, Black SE, et al. Utilitybased quality of life measures in Alzheimer's disease. Qual Life Res 2006;15: 631-43.
25. Banerjee S. Living well with dementia - development of the National Dementia Strategy for England. Int J Geriatr Psychiatr 2010;25: 917-25.
26. Banerjee S, Murray J, Foley B, Atkins L, Schneider J, Mann A. Predictors of institutionalisation in older people with dementia. J Neurol Neurosurg Psychiatr 2003;74: 1315-6.